1. Postponement of proposed Right issue 2. Raising of Funds through Issue of Convertible Equity Share Warrants/Any such other Convertible Securities.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shelter Pharma Ltd's Board of Directors met on June 18, 2025, and approved two key decisions. First, the company has decided to postpone its previously announced Rights Issue (earlier disclosed in January 2025), citing evolving business priorities, execution timelines, and current market conditions. Second, the Board approved raising funds of up to ₹50 Crores through the issuance of Convertible Equity Share Warrants or other convertible securities via Preferential Issue and Private Placement, to be done in one or more tranches. The issue will be subject to shareholder and regulatory approvals. Details on allottees, issue price, and number of securities will be disclosed later.
The postponement of the Rights Issue may delay planned capital raising from existing shareholders, while the new plan to raise up to ₹50 Crores through convertible warrants could lead to dilution in the future upon conversion. Shareholders should watch for further disclosures on pricing and allottees, as this could affect stock price and shareholding pattern.